person · Reporting owner
PRENDERGAST FRANKLYN G
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | Director | November 20, 2017 | November 22, 2017 |
| Immunome Inc.IMNM · Entity 4219 | Director | October 02, 2023 | October 04, 2023 |
| Lantern Pharma Inc.LTRN · Entity 7525 | Director | November 04, 2021 | November 08, 2021 |
| NeuBase Therapeutics, Inc.NBSE · Entity 109568 | Director | September 09, 2022 | September 12, 2022 |
| Vyant Bio, Inc.CGIX · Entity 116415 | Director | July 23, 2019 | August 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date November 20, 2017 · Filed November 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,574 |
Reported balance
After 2017-11-20 transaction · row 1
1 source rowRow 1 · 2017-11-20 · Grant · Acquired 802 · Balance 68,574 |
Immunome Inc.
Report date October 02, 2023 · Filed October 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,840 |
Reported balance
After 2023-10-02 transaction · row 1
1 source rowRow 1 · 2023-10-02 · Grant · Acquired 60,840 · Balance 60,840 F1: In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2032-09-26 | Direct | 137,725 |
Reported balance
After 2023-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-10-02 · Grant · Acquired 137,725 · Balance 137,725 F1: In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer. F2: In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.
F2: In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable.
Lantern Pharma Inc.
Report date November 04, 2021 · Filed November 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.32 · Expires 2031-11-04 | Direct | 3,200 |
Reported balance
After 2021-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-04 · Grant · Acquired 3,200 · Balance 3,200 F1: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing upon December 4, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing upon December 4, 2021.
NeuBase Therapeutics, Inc.
Report date September 09, 2022 · Filed September 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2032-09-09 | Direct | 37,600 |
Reported balance
After 2022-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-09 · Grant · Acquired 37,600 · Balance 37,600 F1: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months.
Vyant Bio, Inc.
Report date July 23, 2019 · Filed August 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.15 · Expires 2029-07-23 | Direct | 100,000 |
Reported balance
After 2019-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-23 · Grant · Acquired 100,000 · Balance 100,000 F1: The options vest monthly in twelve equal installments beginning on August 23, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest monthly in twelve equal installments beginning on August 23, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2023 Filed Oct 4, 2023 21:28 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 137,725 | $1.35 Strike: $1.35 | $185,928.75 |
DisclosureSEC source: 0001209191-23-052048 · doc4.xml · derivative · entry 2 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,725 Underlying: Common Stock · 137,725 shares Expires 2032-09-26 F1 · shares: In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer. F2 · derivative.exercise_date: In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:28 UTC | Immunome Inc. IMNM · Entity 4219 | GrantCommon Stock | 60,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052048 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,840 F1 · shares: In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:51 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001104659-23-070397 · tm2318426-4_4seq1.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 17:01 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 37,600 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001104659-22-099288 · tm2225655-4_4seq1.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,600 Underlying: Common Stock · 37,600 shares Expires 2032-09-09 F1 · derivative.exercise_date: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:03 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001104659-22-073096 · tm2218674-4_4seq1.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-06-16 F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 21:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 3,200 | $0.00 Strike: $10.32 | $0.00 |
DisclosureSEC source: 0001213900-21-057327 · ownership.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires 2031-11-04 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing upon December 4, 2021. Read SEC document |
| August 19, 2021 Filed Sep 17, 2021 16:17 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 38,135 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001104659-21-116924 · tm2127926-2_4seq1.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,135 Underlying: Common Stock · 38,135 shares Expires 2031-08-19 F1 · derivative.exercise_date: 25% of the total shares shall vest on the first anniversary of August 19, 2021, and the remaining shares shall vest on an equal monthly basis over the following 36 months. Read SEC document |
| June 16, 2021 Filed Jun 22, 2021 00:07 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $16.96 | $0.00 |
DisclosureSEC source: 0001104659-21-083670 · tm2118079-12_4seq1.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-06-16 F1 · derivative.exercise_date: The shares subject to the option shall vest one-twelfth (1/12th) every quarter after the grant date. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 17:19 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 14,634 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001104659-20-104488 · tm2030658d1_4.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,634 Underlying: Common Stock · 14,634 shares Expires 2030-09-09 F1 · derivative.exercise_date: 25% of the total shares shall vest on the first anniversary of September 9, 2020, and the remaining shares shall vest on an equal monthly basis over the following 36 months. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 21:33 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option · Derivative | 9,135 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001213900-20-015049 · ownership.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,135 Underlying: Common Stock · 9,135 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's initial public offering ("IPO"). The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date. F1 · price: The Reporting Person was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's initial public offering ("IPO"). The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date. F1 · derivative.exercise_date: The Reporting Person was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's initial public offering ("IPO"). The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date. F1 · derivative.expiration_date: The Reporting Person was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's initial public offering ("IPO"). The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date. Read SEC document |
| July 23, 2019 Filed Aug 21, 2019 17:29 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0000905718-19-000723 · ownership.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock, par value $0.0001 per share · 100,000 shares Expires 2029-07-23 F1 · derivative.exercise_date: The options vest monthly in twelve equal installments beginning on August 23, 2019. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 20:36 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 227,330 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001387131-19-005133 · ownership.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,330 Underlying: Common stock · 227,330 shares Expires 2029-07-12 F1 · derivative.exercise_date: 1/36th of the total shares subject to the option shall vest monthly over three years. Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:02 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 802 | $83.18 | $66,710.36 |
DisclosureSEC source: 0000059478-17-000217 · wf-form4_151136295636158.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,574 Read SEC document |
| September 28, 2017 Filed Oct 2, 2017 17:09 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001349929-17-000083 · wf-form4_150697855216217.xml · derivative · entry 2 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2027-09-28 F2 · derivative.exercise_date: The option vests in two equal installments on September 28, 2018 and September 28, 2019, respectively. Read SEC document |
| September 28, 2017 Filed Oct 2, 2017 17:09 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantCommon Stock, par value $0.0001 per share | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001349929-17-000083 · wf-form4_150697855216217.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: The restricted stock underlying the award vests in two equal installments on September 28, 2018 and September 28, 2019, respectively. Read SEC document |
| June 07, 2017 Filed Jun 8, 2017 16:30 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001349929-17-000043 · wf-form4_149695382379067.xml · derivative · entry 2 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.0001 per share · 10,000 shares Expires 2027-06-07 F2 · derivative.exercise_date: The option vests in two equal installments on June 7, 2018 and June 7, 2019, respectively. Read SEC document |
| June 07, 2017 Filed Jun 8, 2017 16:30 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantCommon Stock, par value $0.0001 per share | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001349929-17-000043 · wf-form4_149695382379067.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: The restricted stock underlying the award vests in two equal installments on June 7, 2018 and June 7, 2019, respectively. Read SEC document |
| November 30, 2016 Filed Dec 1, 2016 22:21 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,088 | $76.64 | $160,024.32 |
DisclosureSEC source: 0000059478-16-000471 · wf-form4_148063089946491.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,904 Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 16:32 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001349929-16-000120 · wf-form4_147639073362969.xml · derivative · entry 2 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.0001 per share · 10,000 shares Expires 2026-10-11 F2 · derivative.exercise_date: The option vests in two equal installments on October 11, 2017 and October 11, 2018, respectively. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 16:32 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantCommon Stock, par value $0.0001 per share | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001349929-16-000120 · wf-form4_147639073362969.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: The restricted stock underlying the award vests in two equal installments on October 11, 2017 and October 11, 2018, respectively. Read SEC document |
| November 30, 2015 Filed Dec 2, 2015 20:30 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,785 | $81.23 | $144,995.55 |
DisclosureSEC source: 0000059478-15-000217 · wf-form4_144908823239151.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,139 Read SEC document |
| November 28, 2014 Filed Dec 2, 2014 21:03 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,155 | $67.29 | $145,009.95 |
DisclosureSEC source: 0000059478-14-000212 · wf-form4_141755420857171.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,810 Read SEC document |
| November 29, 2013 Filed Dec 3, 2013 20:32 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,841 | $51.03 | $144,976.23 |
DisclosureSEC source: 0000059478-13-000103 · wf-form4_138610276737052.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,757 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:42 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055294 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,003 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:52 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058686 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,812 Read SEC document |
| November 30, 2010 Filed Dec 1, 2010 15:15 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4,187 | $34.63 | $144,995.81 |
DisclosureSEC source: 0001209191-10-057442 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,682 Read SEC document |
| November 30, 2009 Filed Dec 1, 2009 21:24 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4,040 | $35.89 | $144,995.60 |
DisclosureSEC source: 0001209191-09-054816 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,670 Read SEC document |
| November 28, 2008 Filed Dec 2, 2008 19:58 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4,513 | $32.13 | $145,002.69 |
DisclosureSEC source: 0001209191-08-063522 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,005 Read SEC document |
| November 30, 2007 Filed Dec 3, 2007 21:09 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,840 | $51.06 | $144,996.20 |
DisclosureSEC source: 0001209191-07-067244 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,623 Read SEC document |
| November 30, 2006 Filed Dec 4, 2006 18:43 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,672 | $54.26 | $144,982.72 |
DisclosureSEC source: 0001209191-06-062603 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,190 Read SEC document |
| November 30, 2005 Filed Dec 1, 2005 21:32 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,500 | $50.51 | $75,757.50 |
DisclosureSEC source: 0001209191-05-060457 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,061 Read SEC document |
| November 30, 2004 Filed Dec 2, 2004 16:09 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 700 | $56.59 | $39,613.00 |
DisclosureSEC source: 0000059478-04-000189 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,173.11 Read SEC document |
| February 17, 2004 Filed Feb 19, 2004 20:09 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantDirector stock option (right to buy) · Derivative | 2,800 | $0.00 Strike: $73.11 | $0.00 |
DisclosureSEC source: 0000059478-04-000077 · doc4.xml · derivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Common Stock · 2,800 shares Expires 2014-02-14 Read SEC document |
| November 26, 2003 Filed Dec 1, 2003 19:04 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-03-000044 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,208.11 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.